LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:
1. Describe the clinical characteristics, presentation, and diagnosis of struma ovarii
2. Be familiar with standard approach to treatment
3. Understand the role of the multi-kinase inhibitor lenvatinib in refractory disease
Session date:
02/14/2019 - 1:00pm to 2:00pm CST
Location:
UCMC
Chicago, IL
60637
United States
See map: Google Maps
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Speaker Name:
Lorraine Canham, MD